London
8 °C
Manchester
6 °C
Glasgow
Dublin
12 °C
Belfast
Washington
Denver
3 °C
Atlanta
10 °C
Dallas
Houston Texas
New Orleans
El Paso
Phoenix
Los Angeles
14 °C
0 °C
25 °C
31 °C
24 °C
Moderna announces positive results for Omicron vaccine / Photo: © AFP
NYSE - LSE
| RBGPF | 100% | 61.84 | $ | |
| RELX | -0.37% | 45.95 | $ | |
| SCS | -0.75% | 13.27 | $ | |
| RIO | -0.31% | 60.43 | $ | |
| RYCEF | -4.71% | 6.79 | $ | |
| GSK | -2.09% | 34.39 | $ | |
| CMSD | -0.02% | 24.725 | $ | |
| CMSC | -0.24% | 24.55 | $ | |
| NGG | 0.4% | 62.37 | $ | |
| VOD | -0.81% | 8.68 | $ | |
| AZN | -0.38% | 65.04 | $ | |
| JRI | -0.23% | 13.21 | $ | |
| BCC | -1.57% | 140.35 | $ | |
| BTI | 0.2% | 35.49 | $ | |
| BP | 1.65% | 29.05 | $ | |
| BCE | -1.38% | 26.84 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
I. Johansson--BTZ
